So, serum exosomal miR‐16‐5p may be utilized as a tumor inhibitor and a feasible biomarker for PD‐L1 inhibitor‐dependent immunotherapy in LUAD via regulating PD‐L1 expression. This evidence concerns the gene CD274 and neoplasm.